1. FDA decision coming soon on Aimmune's contested peanut allergy drug — Roche's Tecentriq fails in bladder cancer trial — Pfizer launches biosims for Roche's 'big three' cancer drugs in the US — See more on our front page news TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Celgene's partnership with Bluebird & Juno

Discussion in 'Celgene' started by anonymous, Dec 11, 2017 at 12:10 PM.

  1. anonymous

    anonymous Guest

    Celgene announces positive results from the trials with its development partners Bluebird Bio and Juno Therapeutics in ASH 2017.

    I think it's an advantage for all the three companies involved; especially for Bluebird Bio.
     

  2. anonymous

    anonymous Guest

    ASCO ‘18 not so impressive but very tough patient population. How will Wall Street react?
     
  3. anonymous

    anonymous Guest

    ASH 2017???
     
  4. anonymous

    anonymous Guest

    bluebird is a disorganized one trick pony with a extremely expensive treatment. Other biotech companies are catching up and everyone knows it